Özçelik, ŞennurGök Yurttaş, AsiyeKahveci, Muhammet U.Sevim, Altuğ MertGül, Ahmet2022-11-112022-11-112023Özçelik, Ş., Gök Yurttaş, A., Kahveci, M. U., Sevim, A. M. & Gül, A. (2023). Aza-BODIPY photosensitizer substituted with phthalonitrile groups: Synthesis, photophysical properties and in vitro tests for breast cancer. Journal of Molecular Structure, 1271. https://doi.org/10.1016/j.molstruc.2022.134019%200022-2860https://doi.org/10.1016/j.molstruc.2022.134019%200022-2860https://hdl.handle.net/20.500.13055/303Turkish Academy of Sciences (TUBA)In photodynamic therapy (PDT), reactive oxygen species (ROS) are generated through dynamic interactions between light of a specific wavelength, a photosensitizer (PS) and molecular oxygen. Nowadays, there has been an increment in the number of studies evaluating the possible utilization of BF2 chelated tetraarylazadipyrromethanes (aza-BODIPYs) as photosensitizers in PDT. In this study, a novel aza-BODIPY with phthalonitrile substituents was synthesized by the esterification reaction of a phthalonitrile derivative namely, 4-((3,4-dicyanophenyl)sulphanyl)benzoic acid with an aza-BODIPY bearing hydroxy groups on the para positions of distal phenyl groups. Aza-BODIPY compound bearing phthalonitrile substituents was characterized by using UV-Vis, fluorescence, H-1-NMR and mass spectroscopy techniques. Photophysical and photochemical properties including fluorescence quantum yield and singlet oxygen yield were determined. In order to explore its photodynamic efficacy, it was tested on a breast cancer cell line (MCF-7 cells) and on a normal healthy cell line (L929 cells) through dark and light cytotoxicity. (c) 2022 Elsevier B.V. All rights reserved.eninfo:eu-repo/semantics/closedAccessAza-BODIPYPhthalonitrilePhotodynamic Therapy (PDT)Dark ToxicityLight ToxicityCancerSynthesisArticle10.1016/j.molstruc.2022.1340191271Q3WOS:0008592826000162-s2.0-85137157990Q2